GLP1R and type 2 diabetes mellitus: Novel anti-diabetic agents, sodium-glucose co-transporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), have shown promising effects on cardiovascular protection in patients with type 2 diabetes (Zinman et al., 2015; Marso et al., 2016; Neal et al., 2017; Wiviott et al., 2018; Gerstein et al., 2019).